|
|
||||||||
1Institute for Experimental Medical Research, 2Department of Cardiothoracic Surgery, 3Center for Clinical Research, and 4Institute for Medical Genetics, Ullevål University Hospital, University of Oslo, Oslo, Norway
Submitted 23 November 2004 ; accepted in final form 6 April 2005
Although increased levels of circulating interleukin (IL)-18 have been demonstrated in patients with cardiovascular diseases, the functional consequences of chronically increased circulating IL-18 with respect to myocardial function have not been defined. Thus we aimed to examine the effects of chronic IL-18 exposure on left ventricular (LV) function in healthy mice. Moreover, to clarify whether IL-18 has direct effects on the cardiomyocyte, we examined effects of IL-18 on cardiomyocytes in vitro. After 7 days of daily intraperitoneal injections of 0.5 µg IL-18 in healthy mice, a 40% (P < 0.05) reduction in the LV maximal positive derivative, a 25% (P < 0.05) reduction in the LV maximal rate of pressure decay, and a 2.8-fold (P < 0.001) increase in the LV end-diastolic pressure were measured, consistent with myocardial dysfunction. Furthermore, we measured a 75% (P < 0.05) reduction in
-adrenergic responsiveness to isoproterenol. IL-18 induced myocardial hypertrophy, and there was a 2.9-fold increase (P < 0.05) in atrial natriuretic peptide mRNA expression in the LV myocardium. In vitro examinations of isolated adult rat cardiomyocytes being stimulated with IL-18 (0.1 µg/ml) exhibited an increase in peak Ca2+ transients (P < 0.05) and in diastolic Ca2+ concentrations (P < 0.05). In conclusion, this study shows that daily administration of IL-18 in healthy mice causes LV myocardial dysfunction and blunted
-adrenergic responsiveness to isoproterenol. A direct effect of IL-18 on the cardiomyocyte in vitro was demonstrated, suggesting that IL-18 reduces the responsiveness of the myofilaments to Ca2+. Finally, induction of myocardial hypertrophy by IL-18 indicates a role for this cytokine in myocardial remodeling.
cytokines; heart failure; contractile function; calcium
This article has been cited by other articles:
![]() |
Q. Yu, R. Vazquez, E. V. Khojeini, C. Patel, R. Venkataramani, and D. F. Larson IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H76 - H85. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-O. Larsen, B. Lygren, I. Sjaastad, K. A. Krobert, K. Arnkvaern, G. Florholmen, A.-K. R. Larsen, F. O. Levy, K. Tasken, O. H. Skjonsberg, et al. Diastolic dysfunction in alveolar hypoxia: a role for interleukin-18-mediated increase in protein phosphatase 2A Cardiovasc Res, October 1, 2008; 80(1): 47 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Doi, T. Sakoda, T. Akagami, T. Naka, Y. Mori, T. Tsujino, T. Masuyama, and M. Ohyanagi Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1279 - H1287. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Platis, Q Yu, D Moore, E. Khojeini, P Tsau, and D. Larson The effect of daily administration of IL-18 on cardiac structure and function Perfusion, July 1, 2008; 23(4): 237 - 242. [Abstract] [PDF] |
||||
![]() |
T. Hoshino, S. Kato, N. Oka, H. Imaoka, T. Kinoshita, S. Takei, Y. Kitasato, T. Kawayama, T. Imaizumi, K. Yamada, et al. Pulmonary Inflammation and Emphysema: Role of the Cytokines IL-18 and IL-13 Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 49 - 62. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway J. Immunol., July 1, 2006; 177(1): 234 - 245. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |